Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth D Westover

Showing results (81-90 of 100) with videos related to

Pageof 10
Sort By:
International Journal of Radiation Oncology, Biology, Physics|August 18, 2015
Precision Hypofractionated Radiation Therapy in Poor Performing Patients With Non-Small Cell Lung Cancer: Phase 1 Dose Escalation TrialKenneth D Westover, Billy W Loo, David E Gerber, et al.
Nature Chemical Biology|October 20, 2014
Pharmacological targeting of the pseudokinase Her3Ting Xie, Sang Min Lim, Kenneth D Westover, et al.
Bioorganic & Medicinal Chemistry|January 1, 2017
Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitorsLi Tan, Deepak Gurbani, Ellen L Weisberg, et al.
Nature Structural & Molecular Biology|October 9, 2021
A structural model of a Ras-Raf signalosomeVenkatesh P Mysore, Zhi-Wei Zhou, Chiara Ambrogio, et al.
Journal of Medicinal Chemistry|July 31, 2014
Discovery of type II inhibitors of TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2)Li Tan, Tyzoon Nomanbhoy, Deepak Gurbani, et al.
The Journal of Clinical Investigation|September 18, 2023
GLUT3 promotes macrophage signaling and function via RAS-mediated endocytosis in atopic dermatitis and wound healingDong-Min Yu, Jiawei Zhao, Eunice E Lee, et al.
Angewandte Chemie (International Ed. in English)|November 22, 2013
Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitorSang Min Lim, Kenneth D Westover, Scott B Ficarro, et al.
Bioorganic & Medicinal Chemistry|December 25, 2016
Structure-guided development of covalent TAK1 inhibitorsLi Tan, Deepak Gurbani, Ellen L Weisberg, et al.
Cell Chemical Biology|April 16, 2019
Leveraging Compound Promiscuity to Identify Targetable Cysteines within the KinomeSuman Rao, Deepak Gurbani, Guangyan Du, et al.
Cell Chemical Biology|August 19, 2017
Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF-α Inhibition for Cancer and Autoimmune DiseaseJuliane Totzke, Deepak Gurbani, Rene Raphemot, et al.
Pageof 10

Showing results (81-90 of 100) with videos related to

Sort By:
Pageof 10
International Journal of Radiation Oncology, Biology, Physics|August 18, 2015
Precision Hypofractionated Radiation Therapy in Poor Performing Patients With Non-Small Cell Lung Cancer: Phase 1 Dose Escalation TrialKenneth D Westover, Billy W Loo, David E Gerber, et al.
Nature Chemical Biology|October 20, 2014
Pharmacological targeting of the pseudokinase Her3Ting Xie, Sang Min Lim, Kenneth D Westover, et al.
Bioorganic & Medicinal Chemistry|January 1, 2017
Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitorsLi Tan, Deepak Gurbani, Ellen L Weisberg, et al.
Nature Structural & Molecular Biology|October 9, 2021
A structural model of a Ras-Raf signalosomeVenkatesh P Mysore, Zhi-Wei Zhou, Chiara Ambrogio, et al.
Journal of Medicinal Chemistry|July 31, 2014
Discovery of type II inhibitors of TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2)Li Tan, Tyzoon Nomanbhoy, Deepak Gurbani, et al.
The Journal of Clinical Investigation|September 18, 2023
GLUT3 promotes macrophage signaling and function via RAS-mediated endocytosis in atopic dermatitis and wound healingDong-Min Yu, Jiawei Zhao, Eunice E Lee, et al.
Angewandte Chemie (International Ed. in English)|November 22, 2013
Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitorSang Min Lim, Kenneth D Westover, Scott B Ficarro, et al.
Bioorganic & Medicinal Chemistry|December 25, 2016
Structure-guided development of covalent TAK1 inhibitorsLi Tan, Deepak Gurbani, Ellen L Weisberg, et al.
Cell Chemical Biology|April 16, 2019
Leveraging Compound Promiscuity to Identify Targetable Cysteines within the KinomeSuman Rao, Deepak Gurbani, Guangyan Du, et al.
Cell Chemical Biology|August 19, 2017
Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF-α Inhibition for Cancer and Autoimmune DiseaseJuliane Totzke, Deepak Gurbani, Rene Raphemot, et al.
Pageof 10